A Phase II, Multicenter, Open-label Single Arm Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study

Trial Profile

A Phase II, Multicenter, Open-label Single Arm Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs BL 8040 (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms COMBAT
  • Sponsors BioLineRx
  • Most Recent Events

    • 20 Jan 2018 Results (n=32) assessing pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, were presented at the 2018 Gastrointestinal Cancers Symposium.
    • 17 Jan 2018 According to a BioLineRx media release, data will be presented at the ASCO 2018 Gastrointestinal Cancers Symposium.
    • 17 Jan 2018 Results published in the BioLineRx Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top